Back to Search
Start Over
Data from Phase III study OASIS 3
- Source :
- Plus Company Updates. September 12, 2024
- Publication Year :
- 2024
-
Abstract
- BERLIN: Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.810874197